Claims:

1. A compound of Formula (I):



Formula (I)

wherein:

$\mathbf{R^1}$ is selected from hydrogen and C_{1-4}alkyl;

$\mathbf{R^2}$ is selected from: $\mathbf{R^4}$-C($\mathbf{R^{5a}R^{5b}}$)- , $\mathbf{R^4}$=C($\mathbf{R^6}$)- and $\mathbf{R^{7a}}$C($\mathbf{R^{7b}}$)=C($\mathbf{R^6}$)-;

$\mathbf{R^3}$–**X-** is selected from methyl, methoxymethyl and



;

$\mathbf{R^4}$ is selected from C_{1-4}alkyl, phenyl, C_{3-6}cycloalkyl and heteroaryl, wherein R^4 is optionally substituted by one or two substituents independently selected from $\mathbf{R^8}$;

$\mathbf{R^{5a}}$ and $\mathbf{R^{5b}}$ are independently selected from hydrogen, fluoro and C_{1-4}alkyl;

$\mathbf{R^6}$ is selected from hydrogen and C_{1-4}alkyl;

$\mathbf{R^{7a}}$ and $\mathbf{R^{7b}}$ are independently selected from C_{1-4}alkyl wherein R^{7a} and R^{7b} are optionally substituted by one or two substituents independently selected from $\mathbf{R^8}$;

$\mathbf{R^8}$ is independently selected from C_{1-3}alkyl, C_{1-3}alkoxy, fluoro and chloro;

with the proviso that:

(i) at least one of $\mathbf{R^{5a}}$ and $\mathbf{R^{5b}}$ is fluoro; and

(ii) when $\mathbf{R^2}$ is $\mathbf{R^4}$=C($\mathbf{R^6}$)- then $\mathbf{R^4}$ is C_{3-6}cycloalkyl;

or a salt, pro-drug or solvate thereof.

2. A compound of formula (I) as claimed in Claim 1, which is a compound of Formula (Ia)



Formula (Ia)

wherein:

$\mathbf{R^1}$ and $\mathbf{R^2}$ are as in claim 1;

or a salt, solvate or pro-drug thereof.

3. A compound of formula (I) as claimed in Claim 1, which is a compound of a compound of Formula (Ic)



Formula (Ic)

wherein:

$\mathbf{R^1}$ and $\mathbf{R^2}$ are as defined in Claim 1;

or a salt, solvate or pro-drug thereof.

4. A compound as claimed in any of claims 1 to 3, wherein R^2 is R^4-C($R^{5a}R^{5b}$)-, or a salt, solvate or pro-drug thereof.

5. A compound as claimed in any of claims 1 to 3, wherein R^2 is R^4=C(R^6)-; or a salt, solvate or pro-drug thereof.

6. A compound of formula (I) as claimed in Claim 1, wherein

$\mathbf{R^1}$ is hydrogen;

$\mathbf{R^2}$ is selected from: $\mathbf{R^4}$-C($\mathbf{R^{5a}R^{5b}}$)- and $\mathbf{R^4}$=C($\mathbf{R^6}$)-;

$\mathbf{R^3}$–**X-** is selected from methyl and methoxymethyl;

$\mathbf{R^4}$ is selected from phenyl and C_{3-6}cycloalkyl, wherein $\mathbf{R^4}$ is optionally substituted by one or two substituents independently selected from $\mathbf{R^7}$;

R^{5a} and R^{5b} are independently selected from hydrogen and fluoro;

R^6 is hydrogen;

R^7 is independently selected from C_{1-3}alkyl, C_{1-3}alkoxy, fluoro and chloro;

with the proviso that:

(iii) at least one of R^{5a} and R^{5b} is fluoro;

(iv) when R^2 is R^4=C(R^6)- then R^4 is C_{3-6}cycloalkyl;

or a salt, solvate or pro-drug thereof.

7. A compound of formula (I) as claimed in Claim 6 wherein R^7 is unsubstituted; or a salt, solvate or pro-drug thereof.

8. A compound of formula (I) as claimed in Claim 6 wherein both R^{5a} and R^{5b} are fluoro; or a salt, solvate or pro-drug thereof.

9. A compound of formula (I) as claimed in Claim 1, which compound is selected from:

6-{[(3-[(2,2-difluoro-2-phenylethyl)oxy]-5-{[(1S)-1-methyl-2-(methyloxy)ethyl]oxy}phenyl)carbonyl]amino}pyridine-3-carboxylic acid;

6-[({3-[(2,2-difluoro-2-phenylethyl)oxy]-5-[(1-methylethyl)oxy]phenyl}carbonyl)amino]pyridine-3-carboxylic acid ;

6-{[(3-[(2-cyclopentylideneethyl)oxy]-5-{[(1S)-1-methyl-2-(methyloxy)ethyl]oxy}phenyl)carbonyl]amino}pyridine-3-carboxylic acid; and

6-{[(3-[(2-cyclopentylideneethyl)oxy]-5-[(1-methylethyl)oxy]phenyl}carbonyl)amino]pyridine-3-carboxylic acid;

or a salt, solvate or pro-drug thereof.

10. A pharmaceutical composition comprising a compound of Formula (I) as claimed in any one of Claims 1 to 9, or a salt, solvate or prodrug thereof, together with a pharmaceutically-acceptable diluent or carrier.

11. A compound of Formula (I), as claimed in any one of Claims 1 to 9, or a salt, solvate or prodrug thereof, for use as a medicament.

12. A compound of Formula (I), as claimed in any one of Claims 1 to 9, or a salt, solvate or prodrug thereof, for use in the preparation of a medicament for treatment of a disease mediated through GLK, in particular type 2 diabetes.

13. A method of treating GLK mediated diseases, especially diabetes, by administering an effective amount of a compound of Formula (I), as claimed in any one of Claims 1 to 9, or a salt, solvate or prodrug thereof, to a mammal in need of such treatment.

14. The use of a compound of Formula (I), as claimed in any one of Claims 1 to 9, or salt, solvate or pro-drug thereof, in the preparation of a medicament for use in the combined treatment or prevention of diabetes and obesity.

15. The use of a compound of Formula (I), as claimed in any one of Claims 1 to 9, or salt, solvate or pro-drug thereof, in the preparation of a medicament for use in the treatment or prevention of obesity.

16. A method for the combined treatment of obesity and diabetes by administering an effective amount of a compound of Formula (I), as claimed in any one of Claims 1 to 9, or salt, solvate or pro-drug thereof, to a mammal in need of such treatment.

17. A method for the treatment of obesity by administering an effective amount of a compound of Formula (I), as claimed in any one of Claims 1 to 9, or salt, solvate or pro-drug thereof, to a mammal in need of such treatment.

18. A process for the preparation of a compound of Formula (I) as claimed in Claim 1, a salt, pro-drug or solvate thereof which comprises:
comprises:

(a) reaction of an acid of Formula (IIIa) or activated derivative thereof with a compound of Formula (IIIb),



Formula (IIIa)



Formula (IIIb);

wherein $\mathbf{P^1}$ is hydrogen or a protecting group; or

(b) de-protection of a compound of Formula (IIIc),



Formula (IIIc)

wherein $\mathbf{P^2}$ is a protecting group; or

(c) reaction of a compound of Formula (IIId) with a compound of Formula (IIIe),



Formula (IIId)



Formula (IIIe)

wherein $\mathbf{X^1}$ is a leaving group and $\mathbf{X^2}$ is a hydroxyl group or $\mathbf{X^1}$ is a hydroxyl group and $\mathbf{X^2}$ is a leaving group and wherein $\mathbf{P^1}$ is hydrogen or a protecting group; or

(d) reaction of a compound of Formula (IIIf) with a compound of Formula (IIIg)



Formula (IIIf)



Formula (IIIg)

wherein X^3 is a leaving group and X^4 is a hydroxyl group or X^3 is a hydroxyl group and X^4 is a leaving group wherein P^1 is hydrogen or a protecting group; or

(e) reaction of a compound of Formula (IIIh) with a compound of Formula (IIIi),



Formula (IIIh)



Formula (IIIi);

wherein X^5 is a leaving group and wherein P^1 is hydrogen or a protecting group;

and thereafter, if necessary:

i) converting a compound of Formula (I) into another compound of Formula (I);

ii) removing any protecting groups;

iii) forming a salt, pro-drug or solvate thereof.